… Randomisation in two experimental arms: vandetanib 100 mg or vandetanib 300 mg.
Analysed as one experimental arm in the meta-analysis. Beva2L: Bevacizumab 2nd line; CALGB: …

… with vandetanib plus docetaxel than with placebo plus docetaxel: … to docetaxel in terms of
OS in second-line treatment, although the pivotal trials involving NSCLC did not use docetaxel …

… synergistic with platinum-containing chemotherapy agents [15]. … Vandetanib has shown
efficacy as a single agent in clinical … docetaxel in the second-line treatment of locally advanced or …

… The combination of ramucirumab plus docetaxel is the most effective treatment option for
second-line chemotherapy in patients with advanced or recurrent NSCLC regardless of the …

… a new treatment strategy for second‐line treatment of such patients but … The second‐line
treatment of locally advanced or advanced … included single‐agent chemotherapy. At present, …

… We herein review recent published data regarding the use of second-line treatment after
failure of standard first-line therapies in BTC patients, with a particular focus on ongoing active …

… Patients who progress on the newer anaplastic lymphoma kinase inhibitors should be
considered for second-line therapy with lorlatinib or systemic chemotherapy. Maintenance therapy …

… treat patients with recurrent or metastatic head and neck squamous cell carcinoma in the
second-line treatment… of any two of the multiple second-line treatment strategies have emerged. …

… pazopanib for second-line therapy of … chemotherapy shortened patient survival and increased
the risk of thrombosis [17]. Moreover, studies on the application of imatinib and vandetanib …

… in patients with previously treated non-small-cell lung cancer [… Vandetanib also inhibits
ABCB1, which could enhance the … the EGFR TKI vandetanib in parental and docetaxel-resistant …